Przedstawiamy wybór publikacji naukowych związanych z immunoterapią IOZK. Możesz użyć filtrów, aby dokonać wyboru według typów nowotworów i metod lub wprowadzić wyszukiwane hasła.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002012-01-01 / Int J Hyperthermia 2012;28(1):9-18https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2012-01-01 / Int J Hyperthermia 2012;28(1):9-182012-01-01 00:00:002019-02-15 09:17:17Effector CD8+ T cell IFN-γ production and cytotoxicity are enhanced by mild hyperthermia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002012-01-01 / J Immunother 2012 Jan;35(1):54-65https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2012-01-01 / J Immunother 2012 Jan;35(1):54-652012-01-01 00:00:002023-03-07 13:05:51A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002011-11-26 / Vaccine 2012 Jun;30(29):4394-7https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2011-11-26 / Vaccine 2012 Jun;30(29):4394-72011-11-26 00:00:002019-02-15 08:52:45Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002011-11-23 / Int. J. Oncol. 2012 Mar;40(3):764-72https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2011-11-23 / Int. J. Oncol. 2012 Mar;40(3):764-722011-11-23 00:00:002019-02-15 08:46:36Therapeutical doses of temozolomide do not impair the function of dendritic cells and CD8+ T cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002011-11-16 / Cancer Immunol. Immunother. 2012 Jun;61(6):865-79https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2011-11-16 / Cancer Immunol. Immunother. 2012 Jun;61(6):865-792011-11-16 00:00:002019-02-15 08:45:53Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002011-11-16 / Int. J. Oncol. 2012 Mar;40(3):840-50https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2011-11-16 / Int. J. Oncol. 2012 Mar;40(3):840-502011-11-16 00:00:002021-11-15 16:57:44Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002011-11-15 / Cancer Lett. 2012 Apr;317(1):56-64https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2011-11-15 / Cancer Lett. 2012 Apr;317(1):56-642011-11-15 00:00:002011-11-15 00:00:00Newcastle disease virus induces apoptosis in cisplatin-resistant human lung adenocarcinoma A549 cells in vitro and in vivo
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002011-11-07 / World Neurosurg 2012 May-Jun;77(5-6):736-44https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2011-11-07 / World Neurosurg 2012 May-Jun;77(5-6):736-442011-11-07 00:00:002019-02-15 08:46:33Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002011-11-02 / J. Immunol. 2011 Dec;187(11):6130-42https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2011-11-02 / J. Immunol. 2011 Dec;187(11):6130-422011-11-02 00:00:002019-02-15 08:40:01Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002011-10-26 / J. Biomed. Biotechnol. 2011;2011:718710https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2011-10-26 / J. Biomed. Biotechnol. 2011;2011:7187102011-10-26 00:00:002019-02-15 09:21:34Safety and clinical usage of newcastle disease virus in cancer therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002011-10-22 / Cancer Immunol. Immunother. 2012 May;61(5):629-41https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2011-10-22 / Cancer Immunol. Immunother. 2012 May;61(5):629-412011-10-22 00:00:002019-02-15 08:52:17Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission
The dermis as a portal for dendritic cell-targeted immunotherapy of cutaneous melanoma
Clinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma
Effector CD8+ T cell IFN-γ production and cytotoxicity are enhanced by mild hyperthermia
Inhibition of checkpoint kinase 1 abrogates G2/M checkpoint activation and promotes apoptosis under heat stress
A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer
Immunotherapy of lung adenocarcinoma patient with Peptide-pulsed dendritic cells: a case report
Immunotherapy for glioma: getting closer to the clinical arena?
The roles of tumor-derived exosomes in cancer pathogenesis
Anti-leukemic activity of Newcastle disease virus strains AF2240 and V4-UPM in murine myelomonocytic leukemia in vivo
Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer
Therapeutical doses of temozolomide do not impair the function of dendritic cells and CD8+ T cells
Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria
Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity
Newcastle disease virus induces apoptosis in cisplatin-resistant human lung adenocarcinoma A549 cells in vitro and in vivo
Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial
Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients
Long-term vaccine therapy with autologous whole tumor cell-pulsed dendritic cells for a patient with recurrent rectal carcinoma
Tumor response and negative distal resection margins of rectal cancer after hyperthermochemoradiation therapy
Safety and clinical usage of newcastle disease virus in cancer therapy
Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission